Charles River Laboratories International (CRL) to Release Earnings on Wednesday

Charles River Laboratories International (NYSE:CRL) is projected to announce its Q4 2025 results before the market opens on Wednesday, February 18th. Analysts expect the company to announce earnings of $2.33 per share and revenue of $986.98 million for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, February 18, 2026 at 8:30 AM ET.

Charles River Laboratories International Stock Performance

NYSE CRL opened at $181.16 on Wednesday. The company’s 50 day simple moving average is $204.63 and its two-hundred day simple moving average is $180.05. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.37 and a quick ratio of 1.10. Charles River Laboratories International has a 1 year low of $91.86 and a 1 year high of $228.88. The stock has a market capitalization of $8.92 billion, a PE ratio of -116.13, a P/E/G ratio of 5.57 and a beta of 1.63.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Geneos Wealth Management Inc. grew its holdings in Charles River Laboratories International by 98.0% in the 2nd quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock worth $44,000 after acquiring an additional 145 shares during the last quarter. Brown Brothers Harriman & Co. grew its stake in shares of Charles River Laboratories International by 62.8% in the third quarter. Brown Brothers Harriman & Co. now owns 482 shares of the medical research company’s stock worth $75,000 after purchasing an additional 186 shares during the last quarter. Osaic Holdings Inc. increased its holdings in Charles River Laboratories International by 24.7% during the 2nd quarter. Osaic Holdings Inc. now owns 1,091 shares of the medical research company’s stock valued at $165,000 after purchasing an additional 216 shares during the period. Humankind Investments LLC bought a new position in Charles River Laboratories International during the 2nd quarter valued at approximately $210,000. Finally, Jones Financial Companies Lllp lifted its holdings in Charles River Laboratories International by 167.6% in the 1st quarter. Jones Financial Companies Lllp now owns 1,715 shares of the medical research company’s stock worth $253,000 after buying an additional 1,074 shares during the period. Institutional investors own 98.91% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently commented on CRL. Citigroup boosted their target price on Charles River Laboratories International from $200.00 to $265.00 and gave the stock a “buy” rating in a research report on Friday, January 16th. Morgan Stanley set a $185.00 price objective on Charles River Laboratories International in a report on Monday, December 1st. JPMorgan Chase & Co. upped their price objective on shares of Charles River Laboratories International from $165.00 to $190.00 and gave the stock a “neutral” rating in a research report on Monday, December 15th. TD Cowen reiterated a “buy” rating on shares of Charles River Laboratories International in a research report on Thursday, January 22nd. Finally, Mizuho set a $215.00 price target on shares of Charles River Laboratories International in a research note on Friday, January 9th. Ten equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $209.46.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.